Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection

Jeffrey L. Americo, Catherine A. Cotter, Patricia L. Earl, Ruikang Liu, Bernard MossProceedings of the National Academy of Sciences 2022 · DOI

TL;DR

This study demonstrates that intranasal (IN) administration of an MVA-based SARS-CoV-2 vaccine elicits superior mucosal immunity, including IgA, and provides more robust protection against respiratory infection compared to intramuscular (IM) vaccination in mice. This suggests that IN delivery of next-generation vaccines could be a more effective strategy for preventing SARS-CoV-2 infection and transmission.

What Problem Does This Paper Address?

Despite the success of current COVID-19 vaccines in preventing severe disease, they often fall short of completely preventing infection and transmission. This limitation is partly attributed to insufficient immune responses in the upper respiratory tract, the primary entry point for the virus. The authors aim to investigate whether a different route of vaccine administration – intranasal (IN) – can induce stronger mucosal immunity and offer better protection against SARS-CoV-2 infection in the respiratory tract compared to the standard intramuscular (IM) route. They hypothesize that IN delivery might be more effective in generating localized immunity at the site of initial viral entry.

Methods

The researchers utilized a modified vaccinia virus Ankara (MVA) vector engineered to express the SARS-CoV-2 spike (S) protein. They compared two administration routes: intramuscular (IM) and intranasal (IN).

Key techniques and approaches included:

  • Live Animal Imaging: Using an MVA vector expressing firefly luciferase (MVA/Luc), they tracked vaccine virus distribution and persistence in mice after IN and IM inoculation. This allowed visualization of where the vaccine "landed" and for how long it remained active.
  • Serological Assays: ELISA was used to measure S-binding IgG antibodies in serum and lung tissue. Pseudovirus neutralization assays (using VSV-G pseudotyped viruses) were employed to quantify neutralizing antibody titers (NT50).
  • Immunological Assays: Flow cytometry was used to analyze antigen-specific CD3+CD8+IFN-γ+ T cell responses in lung tissue.
  • Viral Load Quantification: Infectious SARS-CoV-2 was measured using TCID50 (50% tissue culture infectious dose) assays in lung and nasal turbinate homogenates. Viral RNA (sgN and sgS) was quantified using digital droplet PCR (ddPCR) to assess viral replication.
  • Challenge Studies: Mice were challenged with a lethal dose of SARS-CoV-2 to assess vaccine efficacy in preventing morbidity and mortality.
  • Variant Neutralization Assays: Serum from vaccinated mice was tested against pseudoviruses expressing S proteins from various SARS-CoV-2 variants to assess cross-neutralization.

Datasets

The study utilized the K18-hACE2 transgenic mouse model, which is susceptible to SARS-CoV-2 infection. The challenge virus was SARS-CoV-2 USA-WA1/2019. The study also used pseudoviruses expressing the S proteins of the Wuhan strain and several SARS-CoV-2 variants (Alpha, Beta, E484K, Delta, Delta Plus, Gamma, Lambda, Omicron) for neutralization assays. No new benchmark datasets were introduced; rather, established methods for viral load and antibody quantification were employed.

Key Insights and Ideas

  • Mucosal Immunity is Key: The most striking insight is the superior induction of IgA antibodies in the lungs and blood following intranasal vaccination. IgA is crucial for mucosal immunity, acting as a first line of defense at the entry points of pathogens.
  • IN Vaccination for Respiratory Protection: Intranasal delivery of the MVA-based vaccine led to a more complete and rapid clearance of SARS-CoV-2 from the respiratory tract (nasal turbinates and lungs) compared to intramuscular vaccination. This suggests a direct correlation between mucosal immunity and protection against respiratory infection.
  • Early Viral Control: Intranasal vaccination prevented the detection of infectious virus and viral RNA as early as 2 days post-challenge, indicating either complete prevention or extremely rapid elimination of the infection.
  • T Cell Response Differences: Intranasal vaccination also induced higher levels of antigen-specific CD3+CD8+IFN-γ+ T cells in the lungs, suggesting a more robust cellular immune response at the site of infection.
  • Long-Lasting Immunity: Neutralizing antibodies induced by IM vaccination persisted for over 6 months, demonstrating the durability of the immune response.
  • Cross-Neutralization Potential: Serum from mice vaccinated with the Wuhan strain S protein showed some ability to neutralize pseudoviruses expressing variant S proteins, although with reduced potency against certain variants like Beta and Omicron.

Key Results

  • Viral Clearance: Intranasal vaccination resulted in no detectable infectious SARS-CoV-2 or viral RNA in the nasal turbinates or lungs as early as 2 days post-challenge, whereas intramuscular vaccination allowed for some viral presence, albeit cleared within several days.
  • Antibody Induction: Intranasal vaccination uniquely induced IgA antibodies in the lungs and blood, in addition to IgG. Intramuscular vaccination primarily induced IgG.
  • T Cell Response: Intranasal vaccination led to significantly higher levels of CD3+CD8+IFN-γ+ T cells in the lungs compared to intramuscular vaccination.
  • Durability: Neutralizing antibodies induced by IM vaccination persisted for over 6 months.
  • Variant Neutralization: Serum from vaccinated mice showed reduced but still present neutralization activity against pseudoviruses of various SARS-CoV-2 variants.

Limitations and Future Work

  • Mouse Model: The study was conducted in a K18-hACE2 mouse model, which is highly susceptible to SARS-CoV-2. While useful for demonstrating protection, results may not directly translate to humans.
  • Variant Protection: While cross-neutralization was observed, the reduced potency against certain variants (Beta, Omicron) suggests that further studies are needed to confirm protection against these specific variants in vivo.
  • Transmission: The study focused on protection against infection and morbidity. Future work could investigate whether intranasal vaccination also reduces viral shedding and transmission in animal models.
  • Human Trials: The authors suggest that their findings support the testing of MVA-vectored SARS-CoV-2 vaccines via the intranasal route in human clinical trials, with a focus on assessing subsequent infection rates and transmission. They also highlight the potential of MVA as a safe and effective vaccine vector.

Summary updated

Abstract

Current vaccines have greatly diminished the severity of the COVID-19 pandemic, even though they do not entirely prevent infection and transmission, likely due to insufficient immunity in the upper respiratory tract. Here, we compare intramuscular and intranasal administration of a live, replication-deficient modified vaccinia virus Ankara (MVA)-based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike (S) vaccine to raise protective immune responses in the K18-hACE2 mouse model. Using a recombinant MVA expressing firefly luciferase for tracking, live imaging revealed luminescence of the respiratory tract of mice within 6 h and persisting for 3 d following intranasal inoculation, whereas luminescence remained at the site of intramuscular vaccination. Intramuscular vaccination induced S-binding-Immunoglobulin G (IgG) and neutralizing antibodies in the lungs, whereas intranasal vaccination also induced Immunoglobulin A (IgA) and higher levels of antigen-specific CD3<sup>+</sup>CD8<sup>+</sup>IFN-γ<sup>+</sup> T cells. Similarly, IgG and neutralizing antibodies were present in the blood of mice immunized intranasally and intramuscularly, but IgA was detected only after intranasal inoculation. Intranasal boosting increased IgA after intranasal or intramuscular priming. While intramuscular vaccination prevented morbidity and cleared SARS-CoV-2 from the respiratory tract within several days after challenge, intranasal vaccination was more effective as neither infectious virus nor viral messenger (m)RNAs were detected in the nasal turbinates or lungs as early as 2 d after challenge, indicating prevention or rapid elimination of SARS-CoV-2 infection. Additionally, we determined that neutralizing antibody persisted for more than 6 mo and that serum induced to the Wuhan S protein neutralized pseudoviruses expressing the S proteins of variants, although with less potency, particularly for Beta and Omicron.
BibTeX
@inproceedings{americo2022intranasal,
  author = {Jeffrey L. Americo and Catherine A. Cotter and Patricia L. Earl and Ruikang Liu and Bernard Moss},
  title = {{Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2022},
  doi = {10.1073/pnas.2202069119},
}
Figure